Open AccessFirst-line antiretroviral therapy after single-dose nevirapine exposure in South Africa: a cost-effectiveness analysis of the OCTANE trial
Author(s) -
Andrea Ciaranello,
Shahin Lockman,
Kenneth A. Freedberg,
Michael D. Hughes,
Jennifer Chu,
Judith S. Currier,
Robin Wood,
Charles B. Holmes,
Sandy Pillay,
Francesca Conradie,
James McIntyre,
Elena Losina,
Rochelle P. Walensky
Publication year - 2011
Publication title -
aids
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.195
H-Index - 216
eISSN - 1473-5571
pISSN - 0269-9370
DOI - 10.1097/qad.0b013e3283428cbe
Subject(s) - nevirapine , lopinavir , lopinavir/ritonavir , ritonavir , medicine , pediatrics , virology , viral load , human immunodeficiency virus (hiv) , antiretroviral therapy
The OCTANE trial reports superior outcomes of lopinavir/ritonavir vs. nevirapine-based antiretroviral therapy (ART) among women previously exposed to single-dose nevirapine to prevent mother-to-child HIV transmission. However, lopinavir/ritonavir is 12 times costlier than nevirapine.